Gynecological Health

Gynesonics’ Sonata System Is Now Covered by Cigna for the Treatment of Uterine Fibroids

Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Cigna has released a national coverage policy for treatment of uterine fibroids with the Sonata System.  The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound…

Auransa and POLARISqb Enter Research Collaboration to Find Treatments for Neglected Women’s Diseases Like Endometriosis and PCOS

Auransa, an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research collaboration addressing therapeutics for neglected diseases disproportionately affecting women. The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research.  Auransa…

Cigna Now Covers Hologic’s Acessa Procedure for Uterine Fibroids

Women’s health company Hologic has announced a new parntership with Cigna, one of the largest global health insurance service companies. Cigna has updated its medical policy to cover Hologic’s Acessa Laparoscopic Radiofrequency Ablation (Lap-RFA) procedure (CPT code 58674) as medically necessary. This new coverage further validates laparoscopic radiofrequency ablation (Lap-RFA) as a standard of care for uterine fibroids. The Acessa procedure can…

Ark Surgical Raises $2.1M for its LapBox Tissue Containment System for Laparoscopic GYN Surgery

Israeli femtech startup Ark Surgical has secured $2.1 million in funding for its LapBox containment system for secure removal of large internal organs during laparoscopic GYN surgery. The financing was raised from investors of the Together equity crowdfunding platform alongside the Israeli Innovation Authority and NGT. Ark Surgical has completed the first-in-human (FIH) study demonstrating the safety and effectiveness of the LapBox. Approximately 600,000 hysterectomies…

Myovant and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

An estimated 5 million women in the U.S. suffer from symptoms of uterine fibroids, and an estimated 3 million women are inadequately treated by current medical therapy and require further treatment. Uterine fibroids are noncancerous tumors that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumors in women. In addition to an individual’s genetic…

U.S. Reality TV Personality Cynthia Bailey-Hill Supports Reponsum, a New Fibroid App & Online Patient Community

Today, Real Housewives of Atlanta star Cynthia Bailey-Hill announced her support for Responsum for Fibroids, an online empowerment, knowledge, and support platform for women with uterine fibroids, a condition that affects 70-80% of all women by the age of 50. Provided in partnership with CARE About Fibroids and The White Dress Project—two of the nation’s leading fibroids support organizations—and underwritten with independent support from AbbVie, a global…

DotLab Begins Enrollment in a Multi-Center Cohort Study for Its Non-Invasive Test for Endometriosis

DotLab, a healthcare technology company at the forefront of research and development to combat women’s health conditions, today announced the initiation of EMPOWER, a multi-center cohort study for endometriosis. The EMPOWER Study is designed to support future development activities for DotLab’s non-invasive test to aid in the diagnosis of active endometriosis. Last year, DotLab announced the publication of data in the American Journal…

Chlamydia and Gonorrhea Prevention: Evofem Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100

Evofem has recently announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints with statistically  significant reductions in the risk of chlamydia and gonorrhea infections in women at high risk of infection. “We believe publication of this important manuscript in such a prestigious…